The market for semaglutide, a key diabetes and anti-obesity medication, is currently divided equally between the innovator product from Novo Nordisk and its generic counterparts, which launched just over a month ago. Both segments reported sales of ₹44 crore in April 2023, with the innovator molecule selling 32,000 units compared to 1.37 lakh units of generics. Torrent Pharmaceuticals has emerged as the leader in the generic market, capturing 38% of the market share, primarily due to its unique oral formulations. The overall market for semaglutide has expanded, with total sales rising from ₹48 crore in February to ₹88 crore in April, indicating that generics have attracted new customers rather than merely taking sales from the innovator products. Eli Lilly's Tirzepatide, which utilizes a dual receptor approach for weight loss, continues to lead the market, although its sales dipped slightly during the launch of generics but have since rebounded. This trend suggests that while some doctors prefer innovator products for patients who can afford them, the introduction of generics has made the medication more accessible to a broader audience.